Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The American Academy of Neurology and American Headache Society have released their first updated migraine prevention guideline since 2012. The new framework recommends offering preventive treatment to adults with at least 4 migraine days per month—or when migraines disrupt daily life—and incorporates newer therapies alongside established options. Shared decision-making around cost, side effects, and comorbidities is central to the updated approach.
The American Academy of Neurology (AAN) and American Headache Society (AHS) have jointly released a long-awaited update to their migraine prevention guidelines—the first since 2012. Published simultaneously in Neurology and Headache and endorsed by the American Academy of Family Physicians, the new guidance reflects over a decade of advances in preventive migraine therapy.
The updated guideline broadens the lens for who should receive preventive treatment. Frequency alone isn't the deciding factor—migraine-related impairment and quality of life now play an equally important role. Treatment options span from daily oral medications to injectable therapies given monthly or every three months, and some established drugs (like certain antidepressants and blood pressure medications) can address migraine alongside relevant comorbidities.
Key Takeaways:
Why it matters: With a growing menu of migraine preventive therapies, clinicians needed an updated roadmap. This guideline gives neurologists—and family physicians—a structured, individualized framework to match patients with the right prevention strategy.
